Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Pharmpln
PANTOCID 40 enteric-coated tablets. SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): PANTOCID 40 enteric-coated tablets. COMPOSITION PANTOCID 40: Each tablet contains pantoprazole sodium sesquihydrate equivalent to 40 mg pantoprazole . PHARMACOLOGICAL CLASSIFICATION A.11.4.3 Medicines acting on the gastro-intestinal tract. PHARMACOLOGICAL ACTION Site and mechanism of action Pantoprazole is a proton pump inhibitor, i.e. it inhibits specifically and dose-proportionally H + , K + - ATPase, the enzyme, which is responsible for gastric acid secretion in the parietal cells of the stomach. Pantoprazole is a substituted benzimidazole, which accumulates in the acidic compartment of the parietal cells after absorption. In the parietal cell it is protonated and chemically re-arranged tot the active inhibitor, a cyclic sulphonamide, which binds to the H + , K + -ATPase, thus inhibiting the proton pump and causing suppression of stimulated and basal gastric acid secretion after single and multiple intravenous and oral pantoprazole dosing. Because pantoprazole acts distal to the receptor level, it can influence gastric acid secretion irrespective of the nature of the stimulus. Pantoprazole exerts its full effect in a strongly acidic environment (pH<3) and remains mostly inactive at higher pH values, which explains its selectivity for the acid secreting parietal cells of the stomach. Therefore, the complete pharmacological and therapeutic effect for pantoprazole can only be achieved in the acid- secreting parietal cells. By means of a feedback mechanism this effect is diminished at the same rate as acid secretion is inhibited. Effect on gastric acid secretion Although pantoprazole has a half-life of approximately 1 hour, the antisecretory effect increases during repeated once daily administrat Read the complete document